Health Care
Top 10 Health Care stocks in the US, ranked by X-Ray score
60 companies are ranked; Incyte Corp leads. Of the ten shown, our fair-value models label 8 undervalued, 2 fair and 0 overvalued.
Health care mixes drug makers, medical-device makers, life-science tool companies, hospitals and insurers, which have little in common beyond the label. Loss-making companies often have too few usable valuation models for a fair valueand show "Data under review" until enough models are usable, so check the fair-value label before reading a high rank as cheap.
INCY Incyte Corp
- Highest financial health score on the list
- Fair-value check: Undervalued (+20% vs fair value range)
out of 100
Ranks 2 to 10
-
2
DXCMDexcom Inc
78
- Valuation
- 67
- Growth
- 87
- Profit
- 80
- Health
- 83
-
3
PODDInsulet Corp
72
- Valuation
- 68
- Growth
- 91
- Profit
- 64
- Health
- 67
-
4
RMDResmed Inc
70
- Valuation
- 62
- Growth
- 75
- Profit
- 69
- Health
- 79
-
5
ZTSZoetis Inc.
69
- Valuation
- 89
- Growth
- 48
- Profit
- 72
- Health
- 60
-
6
BSXBoston Scientific Corp
67
- Valuation
- 79
- Growth
- 89
- Profit
- 45
- Health
- 55
-
7
DVADavita Inc.
67
- Valuation
- 95
- Growth
- 61
- Profit
- 62
- Health
- 42
-
8
IDXXIdexx Laboratories Inc
66
- Valuation
- 32
- Growth
- 74
- Profit
- 86
- Health
- 78
-
9
CICigna Group
66
- Valuation
- 96
- Growth
- 68
- Profit
- 51
- Health
- 48
-
10
UHSUniversal Health Services Inc
66
- Valuation
- 95
- Growth
- 76
- Profit
- 45
- Health
- 63
How this list is ranked
- Universe. S&P 500 companies that S&P Dow Jones Indices places in the Health Care sector, scored from SEC filings with confidence High or Medium.
- Score. The X-Ray score (0 to 100) blends valuation, growth, profitability, financial health and dividends, with each lens ranked within the sector.
- Order. Sorted by X-Ray score; ties go to the higher financial-health score.
- Data. Scores come from company filings with the SEC and our own fair-value models. Every figure is our own calculation, dated 22 Oct 2026.
- Limits. Scores describe the past and the present, not the future. A company with less history gets a lower confidence label. Different rules give a different order, which is why the rules are printed here.
Why a ranking by stated rules and not a "best" label: the order changes with the rules, so the rules are published next to the list. See also how the X-Ray Score works.
Health Care · ranked by X-Ray Score
| # | Company | Price | Today | X-Ray | Fair value | To fair value |
|---|---|---|---|---|---|---|
| 1 | 116.93 | +3.08% | 80 | Undervalued | +20% | |
| 2 | 78.32 | −2.42% | 78 | Undervalued | +22% | |
| 3 | 148.12 | +4.38% | 72 | Undervalued | +42% | |
| 4 | RMD Resmed Inc | 253.06 | +2.79% | 70 | Fair | +3% |
| 5 | 82.00 | +2.99% | 69 | Undervalued | +35% | |
| 6 | 46.01 | +3.37% | 67 | Undervalued | +35% | |
| 7 | 186.10 | +5.25% | 67 | Undervalued | +36% | |
| 8 | 315.88 | +3.78% | 66 | Undervalued | +46% | |
| 9 | 566.76 | +2.40% | 66 | Fair | −7% | |
| 10 | 188.13 | +2.88% | 66 | Undervalued | +53% | |
| 11 | 467.31 | +1.72% | 63 | Undervalued | +21% | |
| 12 | 232.22 | +4.85% | 63 | Fair | +3% | |
| 13 | 443.85 | +3.67% | 62 | Fair | −5% | |
| 14 | 1,306.69 | +2.83% | 62 | Fair | −7% | |
| 15 | VEEV Veeva Systems Inc | 322.55 | +0.62% | 61 | Fair | −15% |
| 16 | 155.51 | +2.74% | 61 | Undervalued | +19% | |
| 17 | 445.28 | +2.57% | 60 | Fair | +9% | |
| 18 | 63.00 | +3.08% | 60 | Undervalued | +21% | |
| 19 | 424.98 | +1.91% | 58 | Fair | +14% | |
| 20 | 1,012.34 | −0.31% | 57 | Fair | −6% | |
| 21 | 96.59 | +3.83% | 57 | Fair | +4% | |
| 22 | 307.08 | +3.19% | 56 | Fair | +3% | |
| 23 | 243.28 | +1.82% | 56 | Fair | −4% | |
| 24 | 90.09 | +1.91% | 55 | Fair | −11% | |
| 25 | 98.81 | +4.16% | 55 | Fair | +16% | |
| 26 | 255.64 | −0.71% | 53 | Overvalued | −18% | |
| 27 | 94.48 | +1.83% | 52 | Undervalued | +18% | |
| 28 | 338.48 | −0.57% | 52 | Fair | −2% | |
| 29 | 535.17 | +2.03% | 50 | Fair | −16% | |
| 30 | 267.61 | +3.81% | 49 | Fair | −9% | |
| 31 | 71.42 | +3.49% | 49 | Undervalued | +18% | |
| 32 | 87.45 | +0.90% | 48 | Undervalued | +29% | |
| 33 | AMGN Amgen Inc | 447.28 | +2.04% | 48 | Fair | −13% |
| 34 | 420.97 | −1.05% | 47 | Fair | −6% | |
| 35 | REGN Regeneron Pharmaceuticals, Inc. | 819.09 | +1.67% | 47 | Fair | −3% |
| 36 | 200.42 | +3.13% | 47 | Undervalued | +18% | |
| 37 | 1,684.64 | +0.40% | 47 | Overvalued | −19% | |
| 38 | 61.65 | +4.54% | 46 | Fair | +7% | |
| 39 | 72.62 | −0.03% | 45 | Fair | −1% | |
| 40 | 394.03 | +0.14% | 45 | Fair | −11% | |
| 41 | 253.84 | +5.34% | 44 | Fair | −6% | |
| 42 | 329.93 | +1.91% | 44 | Fair | −9% | |
| 43 | 278.32 | +0.61% | 43 | Fair | −0% | |
| 44 | 86.00 | +1.16% | 42 | Fair | +1% | |
| 45 | 71.24 | +1.42% | 42 | Data under review | – | |
| 46 | ABT Abbott Laboratories | 102.51 | +1.99% | 41 | Fair | −11% |
| 47 | 285.19 | +0.14% | 41 | Fair | −15% | |
| 48 | 173.89 | −2.17% | 40 | Fair | −17% | |
| 49 | 269.40 | −4.76% | 39 | Overvalued | −26% | |
| 50 | 157.19 | +2.36% | 37 | Overvalued | −29% | |
| 51 | 25.65 | +3.85% | 37 | Undervalued | +24% | |
| 52 | 676.54 | −2.52% | 34 | Fair | −12% | |
| 53 | 147.24 | −1.76% | 33 | Overvalued | −22% | |
| 54 | 455.59 | −0.41% | 33 | Fair | +9% | |
| 55 | 30.42 | +1.91% | 31 | Fair | −1% | |
| 56 | 229.75 | −1.76% | 30 | Fair | −10% | |
| 57 | 157.36 | +0.48% | 26 | Fair | −15% | |
| 58 | 18.48 | +0.16% | 25 | Fair | +13% | |
| 59 | 339.66 | −1.51% | 20 | Overvalued | −23% | |
| 60 | 202.63 | −17.57% | 12 | Overvalued | −47% |
X-Ray Score combines valuation, growth, profitability, financial health and dividends, ranked within the sector. Educational only, not financial advice.